知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.022 秒)

    Methods and compositions for peptide synthesis
    4.
    发明授权
    Methods and compositions for peptide synthesis 失效
    肽合成的方法和组合物

    公开(公告)号：US6015881A

    公开(公告)日：2000-01-18

    申请号：US71877

    申请日：1998-05-01

    申请人： Myung-Chol Kang ,  Brian Bray ,  Maynard Lichty ,  Catherine Mader ,  Gene Merutka

    发明人： Myung-Chol Kang ,  Brian Bray ,  Maynard Lichty ,  Catherine Mader ,  Gene Merutka

    IPC分类号： C07K14/16 ,  A61K38/00 ,  C07K5/00

    CPC分类号： C07K14/005 ,  C12N2740/16122

    摘要： The present invention relates, first, to methods for the synthesis of peptides, in particular T-20 (also referred to as "DP-178"; SEQ ID NO:1) and T-20-like peptides. Such methods utilize solid and liquid phase synthesis procedures to synthesize and combine groups of specific peptide fragments to yield the peptide of interest. The present invention further relates to individual peptide fragments which act as intermediates in the synthesis of the peptides of interest (e.g., T-20). The present invention still further relates to groups of such peptide intermediate fragments which can be utilized together to produce full length T-20 and T-20-like peptides.

    摘要翻译： 本发明首先涉及合成肽，特别是T-20（也称为“DP-178”; SEQ ID NO：1）和T-20样肽的方法。 这些方法利用固相和液相合成方法来合成和组合特定肽片段的组合以产生感兴趣的肽。 本发明还涉及在合成目标肽（例如T-20）中充当中间体的单个肽片段。 本发明还涉及可以一起用于产生全长T-20和T-20样肽的这种肽中间体片段的基团。

    Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy
    9.
    发明授权
    Pharmaceutical composition for improved administration of HIV gp41-derived peptides, and its use in therapy 有权
    用于改善HIV gp41衍生肽的给药的药物组合物及其在治疗中的应用

    公开(公告)号：US07045552B2

    公开(公告)日：2006-05-16

    申请号：US10663589

    申请日：2003-09-16

    申请人： David Heilman ,  Jie Di ,  Brian Bray

    发明人： David Heilman ,  Jie Di ,  Brian Bray

    IPC分类号： A61K47/30

    CPC分类号： A61K9/0019 ,  A61K38/162 ,  A61K47/10 ,  A61K47/26

    摘要： Provided is a pharmaceutical composition comprising a solution comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Also provided is a synthetic peptide-containing pharmaceutical composition as a unit dose comprising an aqueous formulation comprised of synthetic peptide in a final concentration of not less than 70 mg/ml in admixture with a polyol; wherein the synthetic peptide is an HIV fusion inhibitor, and wherein the polyol is in a final concentration of no less than 5 weight % and no more than 75 weight % of the pharmaceutical composition. Further provided is a method of treating HIV infection by administering to an HIV-infected individual a pharmaceutical composition according to the present invention.

    摘要翻译： 本发明提供一种药物组合物，其包含与多元醇混合的终浓度不小于70mg / ml的合成肽的溶液; 其中所述合成肽是HIV融合抑制剂，并且其中所述多元醇的终浓度不低于所述药物组合物的5重量％且不大于75重量％。 还提供了含合成肽的药物组合物作为单位剂量，其包含由多元醇混合而成的最终浓度不小于70mg / ml的合成肽的水性制剂; 其中所述合成肽是HIV融合抑制剂，并且其中所述多元醇的终浓度不低于所述药物组合物的5重量％且不大于75重量％。 还提供了通过向HIV感染个体施用根据本发明的药物组合物来治疗HIV感染的方法。